Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

This study has been completed.
Information provided by:
Dey Identifier:
First received: March 27, 2006
Last updated: March 5, 2008
Last verified: March 2008
The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.

Condition Intervention Phase
Drug: Formoterol Fumarate
Drug: Tiotropium Bromide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A 6-Week Double-Blind, Parallel-Group, Active-Controlled Trial to Compare the Efficacy and Safety of Concomitant Treatment of Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by Dey:

Primary Outcome Measures:
  • Measure of lung Function

Secondary Outcome Measures:
  • Change in lung function, vital signs; physical examinations; clinical laboratory assessments; adverse event reporting; patient questionnaires

Estimated Enrollment: 128
Study Start Date: April 2006
Study Completion Date: December 2006
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Medical diagnosis of COPD
  • Current or prior history of cigarette smoking

Exclusion Criteria:

  • Medical diagnosis of asthma
  • Significant condition or disease other than COPD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00308191

United States, Arizona
Research Site
Phoenix, Arizona, United States, 85006
United States, California
Research Site
Los Angeles, California, United States, 90095
Research Site
Sepulveda, California, United States, 91343
Research Site
Walnut Creek, California, United States, 94598
United States, Colorado
Research Site
Colorado Springs, Colorado, United States, 80907
United States, Florida
Research Site
Tamarac, Florida, United States, 33321
United States, Georgia
Research Site
Gainesville, Georgia, United States, 30501
United States, Maine
Research Site
Auburn, Maine, United States, 04210
United States, Michigan
Research Site
Ann Arbor, Michigan, United States, 48105
Research Site
Livonia, Michigan, United States, 48152
United States, Missouri
Research Site
St. Louis, Missouri, United States, 63141
United States, New York
Research Site
Liverpool, New York, United States, 13088
Research Site
Rochester, New York, United States, 14618
United States, Oregon
Research Site
Medford, Oregon, United States, 97504
United States, Pennsylvania
Research Site
Collegeville, Pennsylvania, United States, 19426
United States, Texas
Research Site
El Paso, Texas, United States, 79902
Research Site
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
  More Information

Responsible Party: Director, Clinical Affairs, Dey L.P. Identifier: NCT00308191     History of Changes
Other Study ID Numbers: 201-070
Study First Received: March 27, 2006
Last Updated: March 5, 2008

Keywords provided by Dey:

Additional relevant MeSH terms:
Formoterol Fumarate
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Antagonists
Cholinergic Agents
Anticonvulsants processed this record on April 21, 2017